TL;DR
A November 10 endocrinology roundup reports that testosterone use among women has risen since 2016, often without a documented diagnosis of hypoactive sexual desire disorder. It also notes that the FDA removed certain boxed warnings from more menopause hormone patches, while several medication classes are linked to bone-density loss.
A November 10 endocrinology roundup reported that testosterone use among women has risen since 2016 and is often prescribed without a documented diagnosis of hypoactive sexual desire disorder, the sole evidence-based indication identified in the report. The roundup also noted that the FDA removed boxed warnings covering cardiovascular disease, breast cancer and dementia from prescribing information for more hormone therapy patches used for menopause symptoms, and highlighted medications linked to bone-density loss.
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The testosterone finding was attributed to research published in the Journal of Clinical Endocrinology & Metabolism. The source summary says use among females increased after 2016 and that prescriptions frequently lacked documentation of the indicated diagnosis. It does not provide the study’s patient count, the size of the increase, or the rate of prescribing without a documented diagnosis, so those details cannot be quantified from the report.
The roundup separately reported that the FDA removed boxed warnings about cardiovascular disease, breast cancer and dementia from prescribing information for more hormone therapy patches used to treat menopausal symptoms. It did not identify the specific products or give the date of each label change. The report also relayed a warning from doctors, covered by The New York Times, not to overlook a small increase in breast cancer risk associated with certain hormone therapies.
A third item, based on a Washington Post report, listed oral corticosteroids, aromatase inhibitors, androgen deprivation therapy, anti-seizure medications and selective serotonin reuptake inhibitors as drug classes linked to bone-density loss. The roundup did not specify the size of the risk, the duration or dose associated with it, or whether the same effects apply to every medication in each class.
Prescribing and Bone Risks in Focus
Together, the items point to three different issues relevant to patients and clinicians: whether testosterone is being prescribed for a supported indication, how changes to menopause-therapy labeling should be understood, and whether medicines used for other conditions may affect bone health. The roundup reports trends and safety concerns; it does not establish that every prescription is inappropriate or that every patient taking a listed drug will lose bone density.
The patch update also requires careful interpretation. Removing a boxed warning changes information on product labeling, but the roundup does not say that hormone therapy is risk-free or that all products and patients are affected in the same way. Its inclusion of the separate breast cancer report underscores that concerns about specific risks remain part of the discussion.
For people taking medicines associated with bone loss, the list can help frame a conversation with a clinician, but it is not a reason to stop or change treatment independently. The source offers no individualized risk estimates or clinical recommendations. Decisions depend on the medication, the reason it was prescribed and the patient’s circumstances.
Products Worth Considering
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms up to 1875 ft², Quiet 27 dB Operation, AHAM Verifide, HEPA Sleep Mode, White
Garmin Forerunner 55 GPS Running Watch, Black
Withings Body Smart Wi-Fi and Bluetooth Body Composition Scale
As an affiliate, we earn on qualifying purchases.
Three Separate Endocrine Updates
The source is a short endocrinology news roundup, not a single study or formal clinical guideline. Its items draw on separate publications and news reports, so the findings about testosterone, hormone patches and bone-density loss should not be treated as results from one investigation.
The roundup identifies the Journal of Clinical Endocrinology & Metabolism as the source of the testosterone finding and attributes the patch-warning update to the FDA, with coverage by The Guardian. The discussion of bone-related medication effects is attributed to the Washington Post. It also mentions a separate New York Times report on breast cancer risk, but does not provide underlying study details for that item.
Other developments in the roundup included research on relapse after diabetes remission following metabolic-bariatric surgery and a phase III trial of retatrutide compared with semaglutide. Those items are separate from the three developments covered here and do not supply additional evidence about testosterone prescribing, hormone-patch labeling or medication-related bone loss.
“The FDA removed boxed warnings about cardiovascular disease, breast cancer, and dementia from prescribing information for more hormone therapy patches for menopausal symptoms.”
— MedPage Today roundup, summarizing FDA action
Evidence and Product Details Missing
The roundup does not give the number of women in the testosterone research, the exact increase since 2016, or how often prescriptions lacked a documented diagnosis. It also does not clarify whether missing documentation means the diagnosis was absent or simply not recorded.
For the FDA action, the specific patches, label-change dates and scope of the warning removals are not stated. The source does not explain how the changes relate to the separately reported small increase in breast cancer risk for certain hormone therapies. For the bone-loss list, it provides no estimates of risk, evidence details or guidance about which patients are most affected.
Full Studies and Labels Needed
More detail will depend on reviewing the underlying testosterone study, the FDA’s product-specific labeling and the evidence behind the reported bone-density links. Those materials would help establish the scale of the prescribing trend, which patches had warnings changed and how risk varies across medicines and patients. The roundup does not announce a new guideline, regulatory review or scheduled follow-up.
Until those details are available, the reported developments are best read as a set of issues for clinical discussion rather than a single change in treatment advice. Patients with questions about testosterone, menopause hormone therapy or medicines that may affect bone health should discuss their own treatment with a qualified clinician and should not stop prescribed medication based on a news summary.
Key Questions
What did the report say about testosterone use among women?
It said use among females rose after 2016 and that prescriptions frequently lacked a documented diagnosis of hypoactive sexual desire disorder, described in the summary as the sole evidence-based indication. It did not provide counts or the size of the increase.
Did the FDA remove warnings from every menopause hormone therapy?
The roundup says the FDA removed certain boxed warnings from prescribing information for more hormone therapy patches. It does not name the products, say that every hormone therapy was affected or give the dates of the changes.
Does the patch-label change mean hormone therapy has no breast cancer risk?
No. The roundup separately reports doctors’ warning about a small increase in breast cancer risk associated with certain hormonal therapies. It does not provide enough detail to compare that risk with the FDA label changes or apply it to every product or patient.
Which medication classes were linked to bone-density loss?
The report lists oral corticosteroids, aromatase inhibitors, androgen deprivation therapy, anti-seizure medications and selective serotonin reuptake inhibitors. It does not quantify the risk or say that everyone taking these medicines will experience bone loss.
Should patients stop a medicine because of these reports?
The roundup does not advise patients to stop treatment. Anyone concerned about a prescribed medicine or bone health should discuss their situation with a qualified clinician before making changes.
Source: medpagetoday.com
